[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591414":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":104,"collaborators":11,"id":106,"slug":11,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":11,"eligibilityCriteria":111,"healthyVolunteers":107,"sex":112,"minAge":113,"maxAge":11,"enrollmentInfo":114,"targetDuration":11,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":129,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},{"fullName":5,"class":6},"Exscientia AI Limited","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EXS73565","EXPERIMENTAL",null,[13],"Drug: EXS73565",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","EXS73565 oral administration",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Exscientia AI Ltd.","CONTACT","385-374-1724","clinicaltrials@recursion.com",[26,38,48,58,63,68,77,87,96],{"facility":27,"status":28,"city":29,"state":11,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":11},"LLC ARENSIA Exploratory Medicine","RECRUITING","Tbilisi","119","Georgia",{"type":33,"coordinates":34},"Point",[35,36],44.83412,41.69143,{"lat":36,"lon":35},{"facility":39,"status":28,"city":40,"state":11,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":47,"contacts":11},"IMSP Institute of Oncology, ARENSIA Exploratory Medicine","Chisinau","MD-2025","Moldova",{"type":33,"coordinates":44},[45,46],28.85938,47.00902,{"lat":46,"lon":45},{"facility":49,"status":28,"city":50,"state":11,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":57,"contacts":11},"Hospital Beata Maria Ana","Madrid","28007","Spain",{"type":33,"coordinates":54},[55,56],-3.70256,40.4165,{"lat":56,"lon":55},{"facility":59,"status":28,"city":50,"state":11,"zip":11,"country":52,"cosmosGeoPoint":60,"geoPoint":62,"contacts":11},"Hospital Fundación Jiménez Diaz",{"type":33,"coordinates":61},[55,56],{"lat":56,"lon":55},{"facility":64,"status":28,"city":50,"state":11,"zip":11,"country":52,"cosmosGeoPoint":65,"geoPoint":67,"contacts":11},"Hospital Universitario HM Sanchinarro",{"type":33,"coordinates":66},[55,56],{"lat":56,"lon":55},{"facility":69,"status":28,"city":70,"state":11,"zip":71,"country":52,"cosmosGeoPoint":72,"geoPoint":76,"contacts":11},"Clinica Universidad de Navarra","Pamplona","31008",{"type":33,"coordinates":73},[74,75],-1.64323,42.81687,{"lat":75,"lon":74},{"facility":78,"status":28,"city":79,"state":11,"zip":80,"country":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"Medical Center of LLC ARENSIA Exploratory Medicine","Kyiv","01135","Ukraine",{"type":33,"coordinates":83},[84,85],30.5238,50.45466,{"lat":85,"lon":84},{"facility":88,"status":28,"city":89,"state":11,"zip":11,"country":90,"cosmosGeoPoint":91,"geoPoint":95,"contacts":11},"St James's University Hospital","Leeds","United Kingdom",{"type":33,"coordinates":92},[93,94],-1.54785,53.79648,{"lat":94,"lon":93},{"facility":97,"status":28,"city":98,"state":11,"zip":11,"country":90,"cosmosGeoPoint":99,"geoPoint":103,"contacts":11},"University Hospitals Plymouth NHS Trust (Derriford Hospital)","Plymouth",{"type":33,"coordinates":100},[101,102],-4.14305,50.37153,{"lat":102,"lon":101},{"type":105,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591414",false,"NCT06980116","Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, or waldenström macroglobulinaemia.\n* Participants that have relapsed after standard of care or have progressed during standard of care or are not suitable for standard of care therapy\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the view of the Principal Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Known central nervous system (CNS) malignancy or primary CNS lymphoma.\n* Concurrent active or previous malignancy (other than the primary lymphoma\u002FCLL for which the participant will be treated on this protocol within 5 years prior to randomization; participants with prior cancers may be enrolled with documented Sponsor approval.\n* Received anticancer therapy, including chemotherapy, immunotherapy, radiation therapy (with the exception of palliative radiotherapy), biologic therapy, cancer-related hormonal therapy, or any investigational therapy within 14 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment.","ALL","18 Years",{"count":115,"type":116},85,"ESTIMATED","INTERVENTIONAL",[119],"PHASE1","The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed\u002Frefractory B-cell malignancies.",[122,123,124,125,126,127,128],"Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)","Follicular Lymphoma (FL)","Marginal Zone Lymphoma (MZL)","Mantle Cell Lymphoma (MCL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)",[130,131,124,125,126,127,128,132],"B-cell Malignancies","Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL)","MALT1","2026-06-09",{"date":135,"type":136},"2026-06-11","ACTUAL",{"date":138,"type":136},"2025-03-31",{"date":140,"type":116},"2028-12",{"name":142,"class":6},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",9]